Nascent Biotech (NBIO) 10-Q 9 Feb 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Dec. 31, 2020	Feb. 09, 2021
Cover [Abstract]
Entity Registrant Name	Nascent Biotech Inc.
Entity Central Index Key	0001622057
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2020
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		97,059,154
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Current assets:
Cash	$ 54,672	$ 3,218
Prepaid	18,313	0
Total current assets	72,985	3,218
Total assets	72,985	3,218
Current liabilities:
Accounts payable and accrued liabilities	761,598	852,664
Convertible note- net of discount	109,792	88,815
Derivative liability	226,186	603,836
Note payable	0	50,000
Due to related parties	207,333	1,283,607
Total current liabilities	1,304,909	2,878,922
Total liabilities	1,304,909	2,878,922
Commitments and contingencies	0	0
Stockholders' deficit:
Preferred stock, $0.001 par value, 50,000,000 authorized, 250,000 and 60,000 issued and outstanding	250	60
Common stock, $0.001 par value; 500,000,000 authorized, 91,330,154 and 44,890,262 issued and outstanding, respectively	91,330	44,890
Additional paid-in capital	16,855,917	13,916,995
Accumulated deficit	(18,179,421)	(16,837,649)
Total stockholders' deficit	(1,231,924)	(2,875,704)
Total liabilities and stockholders' deficit	$ 72,985	$ 3,218

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2020	Mar. 31, 2020
Stockholders' deficit
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	250,000	60,000
Preferred stock, shares outstanding	250,000	60,000
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	91,330,154	44,890,262
Common stock, shares outstanding	91,330,154	44,890,262

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Consulting	$ 409,111	$ 181,290	$ 1,129,846	$ 494,300
General and administrative expense	91,923	62,107	260,106	249,625
Research and development	53,903	124,925	277,338	255,578
Loss from operations	(554,937)	(368,232)	(1,667,290)	(969,503)
Other income (expense):
Interest income	1	0	4	6
Change in fair value	(73,810)	0	556,220	0
Financing costs	(31,356)	0	(34,356)	0
Debt discount interest	(4,423)	0	(4,423)	0
Interest expense	(54,981)	(1,920)	(201,927)	(6,249)
Total other income (expense)	(164,570)	(1,920)	325,518	(6,249)
Net loss	$ (719,507)	$ (370,152)	$ (1,341,772)	$ (975,746)
Net loss per share, basic and diluted	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.03)
Weighted average number of shares outstanding, basic and diluted	76,566,884	33,828,331	64,027,487	33,419,628

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT (unaudited) - USD ($)	Total	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance, shares at Mar. 31, 2019		32,646,635
Balance, amount at Mar. 31, 2019	$ (482,164)	$ 32,647	$ 0	$ 12,318,685	$ (12,833,496)
Common stock issued related parties for AP settlement, shares		639,536
Common stock issued related parties for AP settlement, amount	99,000	$ 640	$ 0	98,360	0
Common stock issued to related parties for service, shares		137,872
Common stock issued to related parties for service, amount	25,721	$ 138	$ 0	25,583	0
Common stock issued for warrant exercise, shares		21,427
Common stock issued for warrant exercise, amount	1,071	$ 21	$ 0	1,050	0
Common stock issued for service, shares		50,000
Common stock issued for service, amount	9,550	$ 50	$ 0	9,500	0
Net loss	(273,738)	$ 0	$ 0	0	(273,738)
Balance, shares at Jun. 30, 2019		33,495,470
Balance, amount at Jun. 30, 2019	(620,560)	$ 33,496	$ 0	12,453,178	(13,107,234)
Balance, shares at Mar. 31, 2019		32,646,635
Balance, amount at Mar. 31, 2019	(482,164)	$ 32,647	$ 0	12,318,685	(12,833,496)
Net loss	(975,746)
Preferred shares issued for cash, amount	$ 0
Common Stock issued for cash, shares
Balance, shares at Dec. 31, 2019		35,960,870	110,000
Balance, amount at Dec. 31, 2019	$ (952,509)	$ 35,961	$ 110	12,820,662	(13,809,242)
Balance, shares at Mar. 31, 2019		32,646,635
Balance, amount at Mar. 31, 2019	(482,164)	$ 32,647	$ 0	12,318,685	(12,833,496)
Balance, shares at Mar. 31, 2020		44,890,262	60,000
Balance, amount at Mar. 31, 2020	(2,875,704)	$ 44,890	$ 60	13,916,995	(16,837,649)
Balance, shares at Jun. 30, 2019		33,495,470
Balance, amount at Jun. 30, 2019	(620,560)	$ 33,496	$ 0	12,453,178	(13,107,234)
Common stock issued to related parties for service, shares		27,500
Common stock issued to related parties for service, amount	3,520	$ 28	$ 0	3,492	0
Common stock issued for service, shares		250,000
Common stock issued for service, amount	37,750	$ 250	$ 0	37,500	0
Net loss	(331,856)	$ 0		0	(331,856)
Preferred shares issued for cash, shares			110,000
Preferred shares issued for cash, amount	110,000	$ 0	$ 110	109,890	0
Balance, shares at Sep. 30, 2019		33,772,970	110,000
Balance, amount at Sep. 30, 2019	(801,146)	$ 33,774	$ 110	12,604,060	(13,439,090)
Common stock issued to related parties for service, shares		207,900
Common stock issued to related parties for service, amount	20,789	$ 207	$ 0	20,582	0
Net loss	(370,152)	$ 0	$ 0	0	(370,152)
Common Stock issued for cash, shares		150,000
Common Stock issued for cash, amount	15,000	$ 150	$ 0	14,850	0
Common stock issued for related parties debt, shares		1,830,000
Common stock issued for related parties debt, amount	183,000	$ 1,830	$ 0	181,170	0
Balance, shares at Dec. 31, 2019		35,960,870	110,000
Balance, amount at Dec. 31, 2019	(952,509)	$ 35,961	$ 110	12,820,662	(13,809,242)
Balance, shares at Mar. 31, 2020		44,890,262	60,000
Balance, amount at Mar. 31, 2020	(2,875,704)	$ 44,890	$ 60	13,916,995	(16,837,649)
Common stock issued for service, shares		677,000
Common stock issued for service, amount	85,440	$ 677	$ 0	84,763	0
Net loss	(203,971)	$ 0	$ 0	0	(203,971)
Common stock issued for related parties for service, shares		2,007,000
Common stock issued for related parties for service, amount	190,915	$ 2,007	$ 0	188,908	0
Common stock issued for AP- related parties, shares		13,831,101
Common stock issued for AP- related parties, amount	1,387,872	$ 13,831	$ 0	1,374,041	0
Common stock issued for AP settlement, shares		35,715
Common stock issued for AP settlement, amount	5,000	$ 36	$ 0	4,964	0
Common stock issued for preferred shares, shares		1,352,529	(60,000)
Common stock issued for preferred shares, amount	13,011	$ 1,354	$ (60)	11,717	0
Balance, shares at Jun. 30, 2020		62,793,607
Balance, amount at Jun. 30, 2020	(1,397,437)	$ 62,795	$ 0	15,581,388	(17,041,620)
Balance, shares at Mar. 31, 2020		44,890,262	60,000
Balance, amount at Mar. 31, 2020	$ (2,875,704)	$ 44,890	$ 60	13,916,995	(16,837,649)
Common stock issued for service, shares	1,651,474
Common stock issued for service, amount	$ 144,591
Net loss	(1,341,772)
Preferred shares issued for cash, amount	$ 199,567
Common Stock issued for cash, shares	23,560
Balance, shares at Dec. 31, 2020		91,330,154	250,000
Balance, amount at Dec. 31, 2020	$ (1,231,924)	$ 91,330	$ 250	16,855,917	(18,179,421)
Balance, shares at Jun. 30, 2020		62,793,607
Balance, amount at Jun. 30, 2020	(1,397,437)	$ 62,795	$ 0	15,581,388	(17,041,620)
Common stock issued for service, shares		728,572
Common stock issued for service, amount	44,151	$ 728	$ 0	43,423	0
Net loss	(418,294)	0	$ 0	0	(418,294)
Common Stock issued for cash, shares			640,000
Common Stock issued for cash, amount	640,000	0	$ 640	639,360	0
Preferred stock issued for debt, shares			100,000
Preferred stock issued for debt, amount	100,000	$ 0	$ 100	99,900	0
Common stock issued for service - related parties, shares		918,115
Common stock issued for service - related parties, amount	64,268	$ 918	$ 0	63,350	0
Common stock issued for convertible debt, shares		2,677,397
Common stock issued for convertible debt, amount	150,000	$ 2,677	$ 0	147,323	0
Common stock issued for accounts payable, shares		63,000
Common stock issued for accounts payable, amount	6,300	$ 63	$ 0	6,237	0
Balance, shares at Sep. 30, 2020		67,180,691	740,000
Balance, amount at Sep. 30, 2020	(811,012)	$ 67,181	$ 740	16,580,981	(17,495,914)
Common stock issued for service, shares		245,905
Common stock issued for service, amount	15,000	$ 246	0	14,754	0
Net loss	(719,507)	$ 0	$ 0	0	(719,507)
Common stock issued for service - related parties, shares		4,784,460
Common stock issued for service - related parties, amount	224,028	$ 4,784	$ 0	219,244	0
Common stock issued for convertible debt, shares		1,304,782
Common stock issued for convertible debt, amount	49,567	$ 1,305	0	48,262	0
Common stock issued for conversion of preferred shares, amount	10,000	$ 17,814	$ (490)	(7,324)	0
Common stock issued for conversion of preferred shares, shares		17,814,319	(490,000)
Balance, shares at Dec. 31, 2020		91,330,154	250,000
Balance, amount at Dec. 31, 2020	$ (1,231,924)	$ 91,330	$ 250	$ 16,855,917	$ (18,179,421)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (1,341,772)	$ (975,746)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation - related parties	479,212	50,030
Stock-based compensation	144,591	47,300
(Gain) loss in fair value of derivative liability	(566,220)	0
Debt discount expense	178,652	0
Financing cost	34,356	0
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	(60,650)	314,162
Prepaid	(18,313)	0
Due to related parties	311,598	308,530
Net cash used in operating activities	(838,546)	(255,724)
Cash flows from financing activities:
Common stock issued for exercise of warrants	0	1,071
Proceeds from the sale of preferred shares for cash	640,000	110,000
Proceeds from the sale of common stock for cash	0	15,000
Proceeds from convertible notes	200,000	0
Proceeds from notes payable	50,000	0
Net cash provided by financing activities	890,000	126,071
Net decrease in cash	51,454	(129,653)
Cash -beginning of year	3,218	131,472
Cash -end of period	54,672	1,819
SUPPLEMENT DISCLOSURES:
Interest paid	0	0
Income taxes paid	$ 0	$ 0
Non Cash Transactions
Common stock issued for conversion of preferred shares	23,560
Common stock issued for accrued expenses- related party	$ 1,387,872	$ 282,000
Common stock issued for accounts payable	11,300	0
Common stock issued for convertible debt	199,567	0
Preferred shares issued for notes payable	$ 100,000	$ 0

ORGANIZATION AND NATURE OF OPER

ORGANIZATION AND NATURE OF OPERATIONS	9 Months Ended
	Dec. 31, 2020
ORGANIZATION AND NATURE OF OPERATIONS
NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS	Nascent Biotech, Inc. (“Nascent” or the “Company”) was incorporated on March 3, 2014 under the laws of the State of Nevada. In July, 2014, Jin-En entered into an Exchange Agreement with an entity formerly known as Nascent Biotech, Inc., a Nevada corporation which is now known as Nascent Biologics, Inc. (“Biologics”). As part of the Exchange Agreement, Jin-En changed its name to “Nascent Biotech Inc.” and the entity formerly known as “Nascent Biotech, Inc.”, changed its name to Nascent Biologics, Inc. and became the Company’s wholly owned subsidiary. The Company is actively developing its primary asset Pritumumab for the treatment of brain cancer and pancreatic cancer. Nascent is also actively researching other cancers that have a high probability of benefiting from the therapeutic effects of Pritumumab because they share a common target. Pritumumab has shown to be very effective at low doses in previous clinical studies in Japan. Nascent is a pre-clinical stage biopharmaceutical company that focuses on biologic drug candidates that are preparing for initial clinical testing for the treatment of brain and pancreatic cancer. On March 31, 2017, the Company filed its IND submission with the United States Food and Drug Administration (FDA) for clearance to begin Phase I clinical trials. On December 7, 2018, the Company received a letter from the FDA allowing it to use a specific lot of drug substance to begin phase 1 clinical trials. Due to the low potency testing of the initial lot, this drug substance will not be used in the clinical trials. On October 30, 2020, the Company filed additional data requests and additional testing of the product and additional materials to answer specific questions from the FDA to remove the partial clinical hold. On December 7, 2020, the Company received full clinical clearance from the FDA to begin phase 1 clinical trials on brain cancer patients. Trials are open and scheduled to begin in February 2021, subject to the required financing being received.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Dec. 31, 2020
BASIS OF PRESENTATION
NOTE 2 - BASIS OF PRESENTATION	The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a fiscal year ending on March 31. The accompanying unaudited interim consolidated financial statements of the Company for the three and nine months ended December 31, 2020 and 2019 have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information in accordance with Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s annual report on Form 10-K for the year ended March 31, 2020. In the opinion of management, the unaudited financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the financial position and the results of operations for the interim periods presented herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for any subsequent quarters or for an entire year. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Nascent Biotech, Inc. and its wholly-owned subsidiary Nascent Biologics, Inc. All intercompany accounts and transactions have been eliminated. Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous release’s guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous U.S. GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures. Basis of Presentation The Company computes net loss per share in accordance with ASC 260, Earnings per Share We have identified the conversion features of certain of our convertible notes payable as derivatives. We estimate the fair value of the derivatives using the Black-Scholes pricing model. We estimate the fair value of the derivative liabilities at the inception of the financial instruments, at the date of conversions to equity and at each reporting date, recording a derivative liability, debt discount, and a gain or loss on change in derivative liabilities as applicable. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price volatility and variable conversion prices based on market prices as defined in the respective agreements. These inputs are subject to significant changes from period to period and to management's judgment; therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the fair value recognition provision of the Financial Accounting Standards Board(“FASB”) Accounting Standards Codification (“ASC”) No 718. The Company issues restricted stock to employees and consultants for their services. Cost of these transactions are measured at fair value of the equity instrument issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as the expense in the period granted. The Company recognized consulting expense and a corresponding increase to the additional paid in capital related to the stock issued for services. For agreements requiring future services the consulting expense is to be recognized ratably over the requisite service period. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Financial assets and liabilities recorded at fair value in our condensed consolidated balance sheets are categorized based upon a fair value hierarchy established by GAAP, which prioritizes the inputs used to measure fair value into the following levels: Level 1– Quoted market prices in active markets for identical assets or liabilities at the measurement date. Level 2– Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data. Level 3– Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the instruments. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table summarizes the change in the fair value of the derivative liabilities during the three and nine months ended December 31, 2020: Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2020 $ -- $ -- $ 603,836 Change in fair value at initial issuance 295,126 Change in fair value due to conversion of debt (106,556 ) Change in fair value of the derivative -- -- (566,220 ) Balance at December 31, 2020 $ -- $ -- $ 226,186

GOING CONCERN

GOING CONCERN	9 Months Ended
	Dec. 31, 2020
GOING CONCERN
NOTE 3 - GOING CONCERN	The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has a working capital deficit and has incurred losses from operations. The Company has no revenue to cover its operating costs and the Company will incur additional expenses in the future developing their product. These factors raise substantial doubt about the company’s ability to continue as a going concern. The Company engages in research and development activities that must be satisfied in cash secured through outside funding. The Company may offer noncash consideration and seek equity lines as a means of financing its operations. If the Company is unable to obtain revenue producing contracts or financing or if the revenue or financing it does obtain is insufficient to cover any operating losses it may incur, it may substantially curtail or terminate its operations or seek other business opportunities through strategic alliances, acquisitions or other arrangements that may dilute the interests of existing stockholders. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Dec. 31, 2020
RELATED PARTY TRANSACTIONS
NOTE 4 - RELATED PARTY TRANSACTIONS	On September 1, 2015, the Company entered five-year employment contracts with three of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company as of the date of the contracts. As additional future shares are issued, the officers and directors are entitled to additional shares so their aggregate ownership percentage remains at 11% of the outstanding shares of the Company. On September 1, 2020. the Company renewed the compensation agreements for the Officers of the Company. The agreements set out the compensation as noted in the table below and increased the non-dilutive ownership for the President to 12% and CFO to 6%. The following table sets forth the shares earned under these contracts as of December 31, 2020: Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 5,209,869 6,238,779 Chief Financial Officer 617,346 2,837,523 3,454,869 Executive Vice President (1) 617,346 1,267,553 1,884,899 Total 2,263,602 9,314,945 11,578,547 __________ (1) Effective September 30, 2020 the Executive Vice President left the employment of the Company and maintains a consulting agreement on a as needed basis. During the year ended March 31, 2020 the Board of Directors amended the compensation plan so that the total amount per the officer agreements allow for the accrual of the full amount due each officer per their contract. The table below sets forth the annual amounts per the contracts: Officer and Director Fiscal Year Annualized Compensation Being Paid President $ 250,000 Chief Financial Officer $ 180,000 Executive Vice President (1) $ 140,000 Total $ 570,000 ________ (1) Effective September 30, 2020 the Executive Vice President left the employment of the Company and maintains a consulting agreement on a as needed basis. On July 11, 2019, an officer and director of the Company advanced the Company $10,000. The advance was on demand and bears no interest. On July 26, 2019, the Company repaid the $10,000 advance to the officer and director of the Company. During the nine months ended December 31, 2019 an officer and director of the Company advanced the Company $37,620, $4,250 in cash and $33,370 in payment of accounts payable bills. On December 30, 2019, three officers and directors and the chairman of the Scientific Board of the Company converted $282,000 of accrued fees into 2,469,536 shares of common stock at $0.10- $0.1548 per share. During the nine months ended December 31, 2019, the Company issued 373,272 shares of common stock to three officers and a director for service with a value of $50,030. On December 31, 2019, an officer and director of the Company advanced the Company $14,000 in payment of accounts payable bills During the nine month period ended December 31, 2019 the Company paid the related parties (three officers and directors) $59,000 in consulting fees in cash and accrued $170,000 of the consulting fees for a total of $179,710. In addition $6,209 in expenses were accrued for the related parties. During the nine months ended December 31, 2020 four officers and directors were issued 7,709,575 shares of common stock with a value of $479,212 for service. During the nine months period ended December 31, 2020 three officers of the Company converted $1,387,872 of accrued compensation into 13,831,101 shares of common stock of the Company. During the nine month period ended December 31, 2019 the Company paid the related parties (three officers and directors) $89,000 in consulting fees in cash and accrued $193,333 of the consulting fees for a total of $282,333. In addition $14,000 in expenses were accrued for the related parties. On September 1, 2020, the Company entered five-year compensation agreements with two of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company. In addition, the officers ae entitled to future bonuses including a signing bonus totaling $170,000 which was accrued during the period ending December 31, 2020 plus additional bonuses based on their performance. Officer and Director Fiscal Year Annualized Compensation Base Being Paid Non-dilutive shares percentage President $ 252,000 12 % Chief Financial Officer $ 180,000 6 % Chief Operation Officer $ 162,000 -- Total $ 594,000 18 %

EQUITY

EQUITY	9 Months Ended
	Dec. 31, 2020
EQUITY
NOTE 5 - EQUITY	Preferred On July 25, 2019, the Company issued 110,000 shares of series A convertible preferred to one entity with a value of $110,000 for cash. Each share of series A preferred is convertible after 180 days to four shares of common stock or at the lowest of: (i) the fixed conversion price; (ii) or 70% of the lowest closing price for the 20 days prior to the conversion of the preferred shares. During the nine months period ended December 31, 2020 the Company issued 740,000 shares of Series A preferred stock and 3,700,000 warrants; 640,000 for $640,000 in cash and $100,000 for debt. The stock is convertible into common stock at 10 cents per share or 50% of the lowest trading price, whichever is lower 5 days prior to conversion. The Company has the right to convert the shares nine months after the issuance. The warrants are convertible at $0.15 per share within two years of issuance. In addition the Company agreed to filing an S-1 by September 21, 2020 for the common stock to be converted and the underlying common shares for the warrants. The S-1 has not been filed. During the nine months ended December 31, 2020 the Company issued 17,714,319 shares of common stock for the conversion of 490,000 shares of preferred stock and $8,400 in interest. Common On June 5, 2019, two officers and directors of the Company converted $99,000 of accrued fees into 639,536 shares of common stock at $0.1548 per share. During June 2019, two warrant holders exercised 21,427 warrants for common stock at $0.05 per share for cash of $1,071. On December 11, 2019, the Company issued 150,000 shares of common stock with a value of $15,000 for cash. During the nine months period ended December 31, 2019 Company issued 300,000 shares of common stock to two entities with a value of $47,300 for service. On December 30, 2019, three officers and directors and the chairman of the Scientific Board of the Company converted $282,000 of accrued fees into 2,469,536 shares of common stock at $0.10-$0.1548 per share. During the nine months ended December 31, 2019 the Company issued 373,272 shares of common stock to three officers and a director for service with a value of $50,030. During the nine months ended December 31, 2020 the Company issued 98,715 shares of common stock with a value of $11,300 for settlement of accounts payable. During the nine months ended December 31, 2020 the Company issued 1,651,474 shares of common stock with a value of $144,591 for service. During the nine months ended December 31, 2020 the Company issued 19,166,848 shares of common stock for the conversion of 550,000 shares of preferred stock. During the nine months ended December 31, 2020 three officers and a director were issued 7,709,575 shares of common stock with a value of $479,212 for service. During the nine months ended December 31, 2020, the Company issued 3,982,179 shares of common stock for the conversion of $199,566 of convertible debt and fees. During the nine months period ended December 31, 2020 three officers of the Company converted $1,387,872 of accrued compensation into 13,831,101 shares of common stock of the Company.

OPTIONS

OPTIONS	9 Months Ended
	Dec. 31, 2020
OPTIONS
NOTE 6 - OPTIONS	As of December 31, 2019 there was no option expenses recognized by the Company and the balance of unrecognized option expense was zero. The following sets forth the options granted and outstanding during the nine months ended December 31, 2020: Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2019 1,405,000 $ 0.34 5.80 1,405,000 $ -- Granted -- -- -- -- -- Exercised -- -- -- -- -- Outstanding at December 31, 2020 1,405,000 $ 0.34 5.05 1,405,000 $ -- The weighted average remaining life and intrinsic value of the options as of December 31, 2020, was 5.05 years and zero, respectively.

WARRANTS

WARRANTS	9 Months Ended
	Dec. 31, 2020
WARRANTS
NOTE 7 - WARRANTS	During the nine months ended December 31, 2019 two individuals exercised 21,427 warrants into 21,427 shares of common stock for cash of $1,071. During the nine months ended December 31, 2019 216,320 warrants expired. During the nine months period ended December 31, 2020 the Company granted 3,700,000 warrants to four entities as part of the issuance of 740,000 Series A convertible preferred shares. The warrants expire in two years and convertible into common stock at $0.15 per share. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date, using the following key inputs: market prices of the Company’s common stock at dates of grant between $0.08-0.110 per share, conversion price of $0.15, volatility of 312.5%-314.49% and discount rate of 0.14-0.16%. Based on the fair value of the common stock of $437,000 and recalculated value of the warrants of $349,605 the fair value of the warrants was calculated to be 41 % of the total value or $303,000. During the period ended December 31, 2020 the valuation did not result in a deemed dividend from the down round calculation. As of December 31, 2020 the Company outstanding warrants totaled 3,700,000. Weighted Weighted Average Average Remaining Exercise Contract Intrinsic Warrants Price Life Value Outstanding at March 31, 2019 237,747 $ 0.20 0.25 $ 18,470 Granted -- -- -- -- Exercised (21,427 ) 0.05 -- -- Expired (216,320 ) (0.05 ) -- -- Outstanding at March 31, 2020 -- -- -- -- Granted 3,700,000 0.15 2.0 -- Exercised -- -- -- -- Expired -- -- -- -- Outstanding at December 31, 2020 3,700,000 $ 0.15 1.60 $ --

CONVERTIBLE DEBT

CONVERTIBLE DEBT	9 Months Ended
	Dec. 31, 2020
CONVERTIBLE DEBT
NOTE 8 - CONVERTIBLE DEBT	On December 31, 2019, the Company signed a guaranteed interest rate of 7% Convertible note for $161,250 with an OID of $11,250. The note was funded on January 3, 2020. The note is convertible into common stock of the Company after 180 days at the rate of 60% of the lowest trading price for twenty days prior to conversion or $0.078 whichever is lower. The note may be repaid to the issuer within 180 days from issuance at variable premium rates of 115% to 135% above face value calculated on the outstanding face value of the note plus guaranteed interest. On May 7, 2020, The Company issued an 8% $50,000 one year convertible note. The note is convertible into common stock at the lesser of $0.20 per share or 80% of the lowest closing bid five days prior to conversion. On July 7, 2020, $50,000 of the one year convertible note payable was converted into 50,000 shares of series A preferred On October 28, 2020, the Company issued a $82,500 convertible note with an OID of $7,500. The note matures on October 28,2021 and bears fixed interest of 10%. After 180 days the note may be converted into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion. On November 12, 2020, the Company issued a $138,000 convertible note with an OID of $10,000. The note matures on October 28,2021 and bears interest at 10% per annum. After 180 days the note may be converted into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 212% and expected life of .50 years. During the nine months ended December 31, 2020, the Company issued 2,677,397 shares of common stock for the conversion of $150,000 of convertible debt leaving a principal balance of $11,250.

FAIR VALUE MEASUREMENTS AND DER

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES	9 Months Ended
	Dec. 31, 2020
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES
NOTE 9 - FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES	As defined in (Financial Accounting Standards Board ASC 820), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilized the market data of similar entities in its industry or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. FASB ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities, and listed equities. Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options, and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value As December 31, 2020, the Company believes the amounts reported for cash, payables, accrued liabilities and amounts due to related parties approximate their fair values due to the nature or duration of these instruments. The following table represents the change in the fair value of the derivative liabilities during the nine months ended December 31, 2020: Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2020 $ -- $ -- $ 603,836 Change in fair value at initial issuance 295,126 Change in fair value due to conversion of debt (106,556 ) Change in fair value of the derivative -- -- (566,220 ) Balance at December 31 2020 $ -- $ -- $ 226,186 The estimated fair value of the derivative liabilities at December 31, 2020 was calculated using the Binomial Lattice pricing model with the following assumptions: Risk-free interest rate .18 % Expected life in years 0.25 Dividend yield 0 % Expected volatility 208.00 %

NOTE PAYABLE

NOTE PAYABLE	9 Months Ended
	Dec. 31, 2020
NOTE PAYABLE
NOTE 10 - NOTE PAYABLE	On March 25, 2020, the Company issued a secured note with face value of $50,000. The note matures on July 24, 2020 and bears interest at 7% per annum. In the event of a default the obligation increase to 150% of the outstanding balance and the interest rate increases to 12%. On July 7, 2020 , the $50,000 note payable was converted into 50,000 shares of Series A preferred shares. The interest on the note was forgiven.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Dec. 31, 2020
COMMITMENTS AND CONTINGENCIES
NOTE 11 - COMMITMENTS AND CONTINGENCIES	On September 30, 2016, the Company entered a cell line sales agreement with the product manufacturer. Under the terms of the agreement the Company is obligated to make future payments based on the milestones of its achievements. These future payments may be as followed; 1. $100,000 upon the initiation (first dose/first patient) of the first Phase I clinical trial (or equivalent) of a Product; 2. $225,000 upon the initiation (first dose/first patient) of the first Phase III clinical trial (or equivalent) of a Product 3. $225,000 payable upon the first Biologics License Application approval (or equivalent) of a product. 4. Annual maintenance fee upon completion of phase I manufacturing or the transfer of the cell line from Catalent’s control of $50,000; 5. A contingent sales fee upon first commercial sale of a product of 1% of sales or $150,000 whichever is greater payable quarterly. As of December 31, 2020 $178,000 was due for the annual maintenance fee plus interest. On March 9, 2020, the Board of Directors of the Company adapted an expense bonus program. Under the program, if an acquisition, merger or change in control is affected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocation 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors. On October 30, 2020, the Company signed a term sheet with Alpha Holdings, Inc (Alpha) whereby Alpha, subject to a definitive agreement agreeable to both parties will invest US $ 5,000,000 in the Company. The term sheet outlines the terms of the agreement with a projected closure by December 31, 2020 for an initial investment of $2,500,000 and an additional investment of $2,500,000 on about April 30, 2021. The investment will be in the Company’s common stock to be priced at a low of nine cents per share and a high of 10 cents per share subject to a 90 day weighted average pricing before closing. Upon completion of the $5,000,000 investment Alpha may elect a majority of the board of directors of the Company. The Company has determined that Alpha was treating this as an acquisition and not investment requiring control of the board of directors. the Company determined in the best interest of all shareholders to terminate it discussions with Alpha Holdings, Inc

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Dec. 31, 2020
SUBSEQUENT EVENTS
NOTE 12 - SUBSEQUENT EVENTS	On January 14, 2021, the Company converted 93,428 shares of preferred stock plus interest of $3,171 to 4,200,000 shares of common stock. On January 14, 2021, the S-1 filed by the Company registering 26,300,000 shares of common stock and the underlying shares for 3,700,000 warrants became effective. On February 1, 2021, the Company converted 45,870 shares of preferred stock into 1,529,000 shares of common stock. The Company has evaluated subsequent events to determine events occurring after December 31, 2020 through February 8, 2020 that would have a material impact on the Company’s financial results or require disclosure and have determined none exist other than those noted above in this footnote.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Dec. 31, 2020
BASIS OF PRESENTATION (Policies)
Principle of consolidation	The accompanying consolidated financial statements include the accounts of Nascent Biotech, Inc. and its wholly-owned subsidiary Nascent Biologics, Inc. All intercompany accounts and transactions have been eliminated.
Recent Accounting Pronouncements	In February 2016, the FASB issued ASU No. 2016-02, Leases. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous release’s guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous U.S. GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
Basis of Presentation	The Company computes net loss per share in accordance with ASC 260, Earnings per Share We have identified the conversion features of certain of our convertible notes payable as derivatives. We estimate the fair value of the derivatives using the Black-Scholes pricing model. We estimate the fair value of the derivative liabilities at the inception of the financial instruments, at the date of conversions to equity and at each reporting date, recording a derivative liability, debt discount, and a gain or loss on change in derivative liabilities as applicable. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price volatility and variable conversion prices based on market prices as defined in the respective agreements. These inputs are subject to significant changes from period to period and to management's judgment; therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material.
Stock-Based Compensation	The Company accounts for stock-based compensation in accordance with the fair value recognition provision of the Financial Accounting Standards Board(“FASB”) Accounting Standards Codification (“ASC”) No 718. The Company issues restricted stock to employees and consultants for their services. Cost of these transactions are measured at fair value of the equity instrument issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as the expense in the period granted. The Company recognized consulting expense and a corresponding increase to the additional paid in capital related to the stock issued for services. For agreements requiring future services the consulting expense is to be recognized ratably over the requisite service period.
Fair Value of Financial Instruments	The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Financial assets and liabilities recorded at fair value in our condensed consolidated balance sheets are categorized based upon a fair value hierarchy established by GAAP, which prioritizes the inputs used to measure fair value into the following levels: Level 1– Quoted market prices in active markets for identical assets or liabilities at the measurement date. Level 2– Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data. Level 3– Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the instruments. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table summarizes the change in the fair value of the derivative liabilities during the three and nine months ended December 31, 2020: Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2020 $ -- $ -- $ 603,836 Change in fair value at initial issuance 295,126 Change in fair value due to conversion of debt (106,556 ) Change in fair value of the derivative -- -- (566,220 ) Balance at December 31, 2020 $ -- $ -- $ 226,186

BASIS OF PRESENTATION (Tables)

BASIS OF PRESENTATION (Tables)	9 Months Ended
	Dec. 31, 2020
BASIS OF PRESENTATION
Schedule of Summarizes of change in the fair value of the derivative liabilities	Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2020 $ -- $ -- $ 603,836 Change in fair value at initial issuance 295,126 Change in fair value due to conversion of debt (106.556 ) Change in fair value of the derivative -- -- (566,220 ) Balance at December 31, 2020 $ -- $ -- $ 226,186

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Dec. 31, 2020
RELATED PARTY TRANSACTIONS (Tables)
Schedule of shares earned by related party	Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 5,209,869 6,238,779 Chief Financial Officer 617,346 2,837,523 3,454,869 Executive Vice President (1) 617,346 1,267,553 1,884,899 Total 2,263,602 9,314,945 11,578,547
Schedule of annual salary and annual severance amounts	Officer and Director Fiscal Year Annualized Compensation Being Paid President $ 250,000 Chief Financial Officer $ 180,000 Executive Vice President (1) $ 140,000 Total $ 570,000
Schedule of additional bonus	Officer and Director Fiscal Year Annualized Compensation Base Being Paid Non-dilutive shares percentage President $ 252,000 12 % Chief Financial Officer $ 180,000 6 % Chief Operation Officer $ 162,000 -- Total $ 594,000 18 %

OPTIONS (Tables)

OPTIONS (Tables)	9 Months Ended
	Dec. 31, 2020
OPTIONS
Schedule of Summary of stock options aoutstanding	Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2019 1,405,000 $ 0.34 5.80 1,405,000 $ -- Granted -- -- -- -- -- Exercised -- -- -- -- -- Outstanding at December 31, 2020 1,405,000 $ 0.34 5.05 1,405,000 $ --

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Dec. 31, 2020
WARRANTS
Schedule of Summary of warrants outstanding	Weighted Weighted Average Average Remaining Exercise Contract Intrinsic Warrants Price Life Value Outstanding at March 31, 2019 237,747 $ 0.20 0.25 $ 18,470 Granted -- -- -- -- Exercised (21,427 ) 0.05 -- -- Expired (216,320 ) (0.05 ) -- -- Outstanding at March 31, 2020 -- -- -- -- Granted 3,700,000 0.15 2.0 -- Exercised -- -- -- -- Expired -- -- -- -- Outstanding at December 31, 2020 3,700,000 $ 0.15 1.60 $ --

FAIR VALUE MEASUREMENTS AND D_2

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Tables)	9 Months Ended
	Dec. 31, 2020
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES
Schedule of Fair value of the derivative liabilities	Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2020 $ -- $ -- $ 603,836 Change in fair value at initial issuance 295,126 Change in fair value due to conversion of debt (106,556 ) Change in fair value of the derivative -- -- (566,220 ) Balance at December 31 2020 $ -- $ -- $ 226,186
Schedule of Assumption to calculate fair value of liability	Risk-free interest rate .18 % Expected life in years 0.25 Dividend yield 0 % Expected volatility 208.00 %

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2020
Level 3 [Member]
Fair value of derivative liability, Begnning Balance	$ 603,836	$ 603,836
Change in fair value at initial issuance	295,126	295,126
Change in fair value due to conversion of debt	(106,556)	(106,556)
Change in fair value of the derivative	(566,220)	(566,220)
Ending Balance	226,186	226,186
Level 1 [Member]
Fair value of derivative liability, Begnning Balance	0	0
Change in fair value of the derivative	0	0
Ending Balance	0	0
Level 2 [Member]
Fair value of derivative liability, Begnning Balance	0	0
Change in fair value of the derivative	0	0
Ending Balance	$ 0	$ 0

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	9 Months Ended
	Dec. 31, 2020shares
Initial Share Awards Under the Contracts	2,263,602
Additional Shares Earned to Maintain Ownership Percentage	9,314,945
Total Shares Earned	11,578,547
President [Member]
Initial Share Awards Under the Contracts	1,028,910
Additional Shares Earned to Maintain Ownership Percentage	5,209,869
Total Shares Earned	6,238,779
Chief Financial Officer [Member]
Initial Share Awards Under the Contracts	617,346
Additional Shares Earned to Maintain Ownership Percentage	2,837,523
Total Shares Earned	3,454,869
Executive Vice President [Member]
Initial Share Awards Under the Contracts	617,346
Additional Shares Earned to Maintain Ownership Percentage	1,267,553
Total Shares Earned	1,884,899

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details 1)	9 Months Ended
	Dec. 31, 2020USD ($)
Fiscal Year Annualized Compensation Being Paid	$ 570,000
President [Member]
Fiscal Year Annualized Compensation Being Paid	250,000
Chief Financial Officer [Member]
Fiscal Year Annualized Compensation Being Paid	180,000
Executive Vice President [Member]
Fiscal Year Annualized Compensation Being Paid	$ 140,000

RELATED PARTY TRANSACTIONS (D_3

RELATED PARTY TRANSACTIONS (Details 2)	9 Months Ended
	Dec. 31, 2020USD ($)
Fiscal Year Annualized Compensation Being Paid	$ 594,000
Non-dilutive shares percentage	18.00%
President [Member]
Fiscal Year Annualized Compensation Being Paid	$ 252,000
Non-dilutive shares percentage	12.00%
Chief Finanicial Officer [Member]
Fiscal Year Annualized Compensation Being Paid	$ 180,000
Non-dilutive shares percentage	6.00%
Chief Operation Officer [Member]
Fiscal Year Annualized Compensation Being Paid	$ 162,000

RELATED PARTY TRANSACTIONS (D_4

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended						9 Months Ended
	Dec. 30, 2019	Jul. 26, 2019	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Jul. 11, 2019
Signing bonus amount									$ 170,000
Consulting fees			$ 409,111			$ 181,290			$ 1,129,846	$ 494,300
Common stock, shares issued for services									1,651,474
Common stock, shares issued for services, amount			$ 15,000	$ 44,151	$ 85,440		$ 37,750	$ 9,550	$ 144,591
Common stock valueof accrued compensation							$ 110,000		$ 199,567	0
Four Officers and Directors [Member]
Common stock, shares issued for services									7,709,575
Common stock, shares issued for services, amount									$ 479,212
September 1, 2020 [Member]
Compensation agreements description									The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company. In addition, the officers ae entitled to future bonuses including a signing bonus totaling $170,000 which was accrued during the period ending December 31, 2020 plus additional bonuses based on their performance.
September 1, 2020 [Member] | CFO [Member]
Ownership percentage			6.00%						6.00%
September 1, 2020 [Member] | President [Member]
Ownership percentage			12.00%						12.00%
Three Officers and Director [Member]
Accrued consulting fees related party										170,000
Accrued expenses										6,209
Total consulting fees										179,710
Consulting fees										$ 59,000
Common stock, shares issued for services									7,709,575	373,272
Common stock, shares issued for services, amount									$ 479,212	$ 50,030
Accrued compensation converted amount	$ 282,000								$ 1,387,872
Debt instrument conversion of shares	2,469,536
Common stock shares issued for compensation									13,831,101
Common stock valueof accrued compensation									$ 1,387,872
Three Officers and Director [Member] | Maximum [Member]
Common stock price per share	$ 0.1548
Three Officers and Director [Member] | Minimum [Member]
Common stock price per share	$ 0.10
Three Officers and Director [Member] | December 31, 2019 [Member]
Accrued consulting fees related party									193,333
Accrued expenses									14,000
Total consulting fees									282,333
Consulting fees									$ 89,000
Three Officers and Director [Member] | September 1, 2015 [Member]
Officers and directors employment agreement terms, description									The Company entered five-year employment contracts with three of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company as of the date of the contracts. As additional future shares are issued, the officers and directors are entitled to additional shares so their aggregate ownership percentage remains at 11% of the outstanding shares of the Company.
One Officers And Director [Member]
Related party advance						37,620				37,620	$ 10,000
Payment of cash										4,250
Payment of account payable bill										33,370
Advance amount upon payment of account payable bill						$ 14,000				$ 14,000
Repayment of related part debt		$ 10,000

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)	Nov. 12, 2020	Jul. 07, 2020	Dec. 11, 2019	Oct. 28, 2020	Dec. 30, 2019	Jul. 25, 2019	Jun. 05, 2019	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Settlemet of accounts payable													$ 11,300
Common stock share issued for cash, shares			150,000
Common stock share issued for cash, amount			$ 15,000
Common stock shares issued upon conversion of debt													3,982,179
Debt instrument converted amount													$ 199,566
Common stock shares value for services, amount								$ 15,000	$ 44,151	$ 85,440	$ 37,750	$ 9,550	$ 144,591
Common stock shares issued for services													1,651,474
Common shares issued, for settlement of accounts payable													98,715
Common stock shares, issued								91,330,154					91,330,154		44,890,262
Preferred stock, shares issued								250,000					250,000		60,000
Outstanding warrants, granted													0
Preferred stock shares, value										$ 13,011
Common stock, price per share								$ 0.001					$ 0.001		$ 0.001
Two warrant holders [Member]
Warrants exercised value												$ 1,071
Common stock, price per share												$ 0.05
Warrants Exercised												21,427
One Individual [Member]
Common stock shares issued for services														47,300
Common stock shares, issued														300,000
Series A Convertible Preferred Stock [Member]
Common stock shares issued upon conversion of debt		50,000											19,166,848
Debt instrument converted amount		$ 50,000											$ 550,000
Conversion of preferred stock shares issued								490,000					490,000
Interest								$ 8,400					$ 8,400
Common stock shares, issued								17,714,319					17,714,319	300,000
Preferred stock, shares issued						110,000		740,000					740,000
Conversion description	After 180 days the note may be converted into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion.			After 180 days the note may be converted into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion.		Each share of series A preferred is convertible after 180 days to four shares of common stock or at the lowest of: (i) the fixed conversion price; (ii) the equitant of 70% of the lowest closing price for the 20 days prior to the conversion of the preferred shares.
Outstanding warrants, granted													3,700,000
Preferred stock issued for cash, shares													640,000
Debt								$ 100,000					$ 100,000
Convertible, description													The stock is convertible into common stock at 10 cents per share or 50% of the lowest trading price, whichever is lower 5 days prior to conversion. The Company has the right to convert the shares nine months after the issuance. The warrants are convertible at $0.15 per share within two years of issuance.
Preferred stock shares, value						$ 110,000
Maximum [Member]
Common stock, price per share								$ 0.110					$ 0.110
Three Officers and Director [Member]
Common stock shares value for services, amount													$ 479,212	$ 50,030
Common stock shares issued for services													7,709,575	373,272
Common stock shares, issued														373,272
Common stock shares issued for compensation, shares													13,831,101
Debt instrument conversion of shares					2,469,536
Accrued compensation converted amount					$ 282,000								$ 1,387,872
Three Officers and Director [Member] | Maximum [Member]
Common stock price per share					$ 0.1548
Three Officers and Director [Member] | Minimum [Member]
Common stock price per share					$ 0.10
Two Officers And Director [Member]
Accrued compensation converted amount							$ 99,000
Accrued fees converted amount, shares							639,536
Conversion price per share							$ 0.1548

OPTIONS (Details)

OPTIONS (Details)	9 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Options
Number of option Outstanding, Beginning	1,405,000
Outstanding option, granted	0
Outstanding option, exercised	0
Number of option outstanding, ending	1,405,000
Weighted average exercise price
Weighted average exercise price, Beginning | $ / shares	$ 0.34
Weighted average exercise price, Granted | $ / shares	0
Weighted average exercise price, Exercised | $ / shares	0
Weighted average exercise price, Ending | $ / shares	$ 0.34
Weighted Average Remaining Contract Life
Weighted Average Remaining Contract life, Beginning	5 years 9 months 18 days
Weighted Average Remaining Contract life, Ending	5 years 18 days
Number of option exercisable
Outstanding option, Beginning	1,405,000
Outstanding option, granted	0
Outstanding option, exercised	0
Outstanding option, Ending	1,405,000
Intrinsic value
Intrinsic value, Beginning | $	$ 0
Intrinsic value, granted | $	0
Intrinsic value, exercised | $	0
Intrinsic value, ending | $	$ 0

OPTIONS (Details Narrative)

OPTIONS (Details Narrative) - Option 1 [Member]	9 Months Ended
	Dec. 31, 2020USD ($)
Intrinsic value	$ 0
Weighted average remaining life	5 years 18 days

WARRANTS (Details)

WARRANTS (Details) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Intrinsic value
Outstanding warrants, granted	0
Outstanding warrants, Expired		216,320
Weighted average exercise price, Granted	$ 0
Weighted average exercise price, Exercised	$ 0
Intrinsic value, Beginning	$ 0
Warrants [Member]
Intrinsic value
Outstanding warrants, Beginning			237,747
Outstanding warrants, granted	3,700,000
Outstanding warrants, Exercised			(21,427)
Outstanding warrants, Expired			(216,320)
Outstanding warrants, Ending	3,700,000
Weighted average exercise price, Beginning			$ 0.20
Weighted average exercise price, Granted	$ 0.15		0
Weighted average exercise price, Exercised	0		0.05
Weighted average exercise price, Expired	0		(0.05)
Weighted average exercise price, Ending	$ 0.15		$ 0
Weighted Average Remaining Contract life, Beginning			2 months 30 days
Weighted Average Remaining Contract life, granted	2 years
Weighted Average Remaining Contract life, Ending	1 year 7 months 6 days
Intrinsic value, Beginning			$ 18,470

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020	Jun. 30, 2019
Fair value of common stock	$ 437,000
Warrants, Expired		216,320
Conversion price	$ 0.15
Fair value of the warrants calculation description	The fair value of the warrants was calculated to be 41 % of the total value or $303,000.
Recalculated value of warrants	$ 349,605
Outstanding warrants	3,700,000
Common stock price per share	$ 0.001		$ 0.001
Preferred stock shares issued	250,000		60,000
Four Entities [Member] | Series A Convertible Preferred Stock [Member]
Outstanding warrants	3,700,000
Preferred stock shares issued	740,000
Price per share	$ 0.15
Warrants expiry term	2 years
Maximum [Member]
Common stock price per share	$ 0.110
Discount rate	0.16%
Volatility	314.49%
Minimum [Member]
Common stock price per share	$ 0.08
Discount rate	0.14%
Volatility	312.50%
Two warrant holders [Member]
Warrants exercised		21,427
Common stock issued upon warrant exercised		21,427
Proceeds from exercise of warrants		$ 1,071
Common stock price per share				$ 0.05

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative) - USD ($)	Nov. 12, 2020	Jul. 07, 2020	May 07, 2020	Oct. 28, 2020	Dec. 31, 2019	Jul. 25, 2019	Dec. 31, 2020
Common stock shares issued upon conversion of debt							3,982,179
Debt instrument converted amount							$ 199,566
Risk free interest rate							0.18%
Volatility rate							208.00%
Expected life							2 months 30 days
Series A Convertible Preferred Stock [Member]
Common stock shares issued upon conversion of debt		50,000					19,166,848
Debt instrument converted amount		$ 50,000					$ 550,000
Convertible debt	$ 138,000			$ 82,500
Conversion price, Description	After 180 days the note may be converted into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion.			After 180 days the note may be converted into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion.		Each share of series A preferred is convertible after 180 days to four shares of common stock or at the lowest of: (i) the fixed conversion price; (ii) the equitant of 70% of the lowest closing price for the 20 days prior to the conversion of the preferred shares.
Debt instrument original issue discount	$ 10,000			$ 7,500
Risk free interest rate	18.00%
Volatility rate	212.00%
Debt maturity date	Oct. 28, 2021			Oct. 28, 2021
Expected life	50 years
Interest rate	10.00%			10.00%
7% Convertible Note [Member]
Original issue discount					$ 11,250
Convertible debt					$ 161,250
Conversion price, Description					The note is convertible into common stock of the Company after 180 days at the rate of 60% of the lowest trading price for twenty days prior to conversion or $0.078 whichever is lower. The note may be repaid to the issuer within 180 days from issuance at variable premium rates of 115% to 135% above face value calculated on the outstanding face value of the note plus guaranteed interest
8% Convertible Note [Member]
Convertible debt			$ 50,000
Conversion price, Description			The note is convertible into common stock at the lesser of $0.20 per share or 80% of the lowest closing bid five days prior to conversion.
Convertible Debt [Member]
Common stock shares issued upon conversion of debt							2,677,397
Debt instrument converted amount							$ 150,000
Original issue discount							$ 11,250

FAIR VALUE MEASUREMENTS AND D_3

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Details) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Change in fair value due to conversion of debt		$ 178,652	$ 0
Level 3 [Member]
Fair value of derivative liability		603,836
Change in fair value at initial issuance	$ 295,126	295,126
Change in fair value due to conversion of debt		(106,556)
Change in fair value of the derivative		(556,220)
Total fair value of derivative liability		226,186
Level 2 [Member]
Fair value of derivative liability		0
Change in fair value of the derivative		0
Total fair value of derivative liability		0
Level 1 [Member]
Fair value of derivative liability		0
Change in fair value of the derivative		0
Total fair value of derivative liability		$ 0

FAIR VALUE MEASUREMENTS AND D_4

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Details 1)	9 Months Ended
	Dec. 31, 2020
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES
Risk-free interest rate	0.18%
Dividend yield	0.00%
Expected life in years	2 months 30 days
Expected volatility	208.00%

NOTE PAYABLE (Details Narrative

NOTE PAYABLE (Details Narrative) - USD ($)	Jul. 07, 2020	Mar. 25, 2020	Dec. 31, 2020
Common stock shares issued upon conversion of debt			3,982,179
Debt instrument converted amount			$ 199,566
Secured Note [Member]
Secured note description		The note matures on July 24, 2020 and bears interest at 7% per annum. In the event of a default the obligation increase to 150% of the outstanding balance and the interest rate increases to 12%.
Face value		$ 50,000
Maturity date		Jul. 24, 2020
Interest rate		7.00%
Secured Note [Member] | Series A Convertible Preferred Stock [Member]
Common stock shares issued upon conversion of debt	50,000
Debt instrument converted amount	$ 50,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Mar. 09, 2020	Oct. 30, 2020	Sep. 30, 2016	Dec. 31, 2020
Acquisition merger description	Under the program, if an acquisition, merger or change in control is affected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocation 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors.
Contingent sales fee description			A contingent sales fee upon product sales of 1% of sales or $150,000 whichever is greater.
Annual Maintenance				$ 178,000
First BLA [Member]
Future payments			$ 225,000
First Phase III clinical trial [Member]
Future payments			225,000
First Phase I clinical trial [Member]
Future payments			100,000
Annual maintenance fee			$ 50,000
April 30, 2021 [Member] | Alpha Holdings Inc. [Member]
Investment, amount		$ 5,000,000
Initial investment				2,500,000
Additional investment payment				2,500,000
Board of Directors [Member]
Investment, amount				$ 5,000,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jan. 14, 2021	Dec. 31, 2020
Common stock shares issued upon conversion of debt		3,982,179
February 1, 2021 [Member]
Common stock shares issued upon conversion of debt		45,870
Total shares of common stock		1,529,000
Subsequent Event [Member]
Total register shares of common stock	26,300,000
Underlying warrants	3,700,000
Subsequent Event [Member] | Series A Convertible Preferred Stock [Member]
Common stock shares issued upon conversion of debt	93,428
Common stock, shares	4,200,000
Interest amount	$ 3,171